Sandoz opens high-volume biosimilar drug-substance manufacturing center in Slovenia
The Lendava site expands in-house production capacity and supply flexibility across Sandoz’s European biosimilar network.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Sandoz opens high-volume biosimilar manufacturing centre in Lendava
The facility in Slovenia is designed to strengthen Sandoz's in-house biosimilar production capacity and flexibility across its European network. The company says the centre employs over 300 experts and complements sites in Toulouse and Ljubljana.
Sandoz to invest in Ljubljana drug-substance facility to expand biosimilar capacity
Sandoz Group AG plans to invest in a new drug-substance facility in Ljubljana, Slovenia, to expand biosimilar manufacturing capacity.